Obtenga las últimas noticias sobre las acciones de Tevogen Bio Holdings con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de TVGN

Últimas noticias sobre

TEVOGEN BIO HOLDINGS INC

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

Tevogen Bio Holdings Inc

Press Releases

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Health Care

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

General

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Penny Stocks

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

MSFT

TVGNW

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Agenus

Anika Therapeutics

Anixa Biosciences

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Climb Bio

Coya Therapeutics

Citius Oncology

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Opus Genetics

MDxHealth

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Oncolytics Biotech

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Spero Therapeutics

Surrozen

TScan Therapeutics

Instil Bio

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

D. Boral Capital

Comments

Tevogen Bio Holdings Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL